Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
TB-500 is a synthetic peptide that may support tissue repair and reduce inflammation, but human safety data remain limited. Reported side effects range from mild injection-site reactions, headaches, fatigue, and fluid retention to unknown long-term risks involving immune function and cancer.
Your individual risk depends on several factors, including product quality verification, adherence to professional dosing guidance, sterile injection practices, and regular lab monitoring. Review the complete details below before starting TB-500.
If you're experiencing symptoms you suspect may be linked to TB-500 use or an underlying condition, don't guess—get clarity in minutes. Take a free, instant, and confidential symptom check to better understand what may be happening in your body and identify the right next steps. Built with physicians and powered by medical AI, it can help you decide whether to adjust your regimen, consult a doctor, or seek urgent care—before minor issues become serious ones.
Reviewed for medical accuracy: 07/10/2026
TB-500 (Thymosin Beta-4 fragment) has gained popularity among athletes, biohackers, and those seeking faster recovery from injuries. But with limited human data, it's natural to worry about TB-500 side effects. This guide breaks down what we know, what remains unclear, and the steps you can take to protect your health.
Important: Most research on TB-500 comes from animal studies or cell cultures. Human clinical trials are scarce, so safety and efficacy in people are not fully established.
Although robust human data are lacking, anecdotal reports and early studies suggest some possible side effects:
Injection-site reactions
Headache or dizziness
Fatigue or lethargy
Nausea or upset stomach
Changes in mood or sleep
Fluid retention
Because TB-500 isn't FDA-approved, product purity and exact dosing can vary widely. Some side effects may stem from contaminants, improper storage, or inaccurate labeling rather than TB-500 itself.
Beyond the commonly reported effects, there are risks we simply do not yet understand:
Immune modulation
Cancer concerns
Hormonal interactions
Long-term safety
If you're considering TB-500, take these precautions:
Source verification
Appropriate dosing
Injection hygiene
Baseline labs
Monitor closely
Limit duration
Most injection-site reactions or mild headaches are not emergencies. However, contact a medical professional if you experience:
If you're experiencing any unusual or persistent symptoms and want to better understand what might be happening, you can use Ubie's free AI-powered symptom checker to evaluate your symptoms and get personalized guidance on your next steps.
Consult a Physician Before You Begin
Regular Follow-Ups
Adjust or Discontinue as Needed
Explore Alternative Therapies
Before starting TB-500, ask yourself:
TB-500 side effects can range from mild injection-site discomfort to more serious, yet still poorly understood, risks. By sourcing quality product, using proper dosing, and partnering with a knowledgeable healthcare provider, you can reduce—but not eliminate—potential harms.
If you notice any concerning reactions or life-threatening symptoms, always speak to a doctor right away. Your health is paramount, and professional guidance ensures you're making informed choices.
Stay proactive, stay informed, and prioritize safety every step of the way.
(References)
* Philpot RM, Gressley A, Ma X, Zisman N, Skelley W, King T, Goldstein AL. Safety, tolerability, and pharmacokinetics of multiple ascending doses of recombinant human thymosin beta 4 in healthy subjects. J Clin Pharmacol. 2010 Sep;50(9):1041-50. doi: 10.1177/0091270009355792. Epub 2010 Feb 24. PMID: 20185671.
* Goldstein AL, Gressley A, King T, Zisman N, Skelley W, Ma X, Philpot RM. Safety and efficacy of thymosin β4 in patients with non-arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2012 Sep;32(3):218-24. doi: 10.1097/WNO.0b013e3182664b52. PMID: 22820306.
* Goldstein AL, Gressley A, King T, Ma X, Zisman N, Skelley W, Philpot RM. Safety and pharmacokinetics of intravenous thymosin beta-4 in patients with acute myocardial infarction. Clin Pharmacol Ther. 2010 Oct;88(4):534-8. doi: 10.1038/clpt.2010.165. Epub 2010 Sep 1. PMID: 20811340.
* Goldstein AL, Zisman N, King T, Gressley A, Skelley W, Ma X, Philpot RM. Recombinant human thymosin beta 4 in patients with acute myocardial infarction (REACT trial): a randomized, placebo-controlled, dose-escalation study. J Cardiovasc Transl Res. 2010 Jun;3(3):288-97. doi: 10.1007/s12265-010-9195-2. Epub 2010 May 20. PMID: 20485906.
* Goldstein AL, Zisman N, Skelley W, King T, Gressley A, Ma X, Philpot RM. A phase 2 study of RGN-352 (thymosin beta 4) for patients with non-arteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2014 Mar;132(3):324-30. doi: 10.1001/jamaophthalmol.2013.7712. PMID: 24336946.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.